Literature DB >> 11174494

Maternal plasma vascular endothelial growth factor concentrations in normal and hypertensive pregnancies and their relationship to peripheral vascular resistance.

P M Bosio1, T Wheeler, F Anthony, R Conroy, C O'herlihy, P McKenna.   

Abstract

OBJECTIVE: The aim of this study was to measure maternal plasma vascular endothelial growth factor concentrations during normal and hypertensive pregnancies and examine their relationship with maternal total peripheral resistance values. STUDY
DESIGN: Plasma concentrations of total immunoreactive vascular endothelial growth factor and total peripheral resistances were measured serially throughout pregnancy in 20 women with preeclampsia, 24 women with gestational hypertension, and 26 normotensive control women. One-way analysis of variance and a regression model were used to analyze the vascular endothelial growth factor levels in the groups and the relationship between vascular endothelial growth factor concentration and total peripheral resistance.
RESULTS: At 10 to 14 weeks' gestation plasma vascular endothelial growth factor concentrations in all subjects were 4 to 5 times greater than the levels measured post partum (P <.0001). Mean vascular endothelial growth factor concentrations were similar in the control and gestational hypertension groups; in both groups levels remained stable until 34 to 36 weeks' gestation, when levels increased a further 1.3-fold (P <.01). In comparison, vascular endothelial growth factor concentrations in subjects in the preeclampsia group were greater at 28 to 32 weeks' gestation (P =.002) and at 34 to 36 weeks' gestation (P <.001). Vascular endothelial growth factor concentrations were also increased during the 4 weeks that preceded the diagnosis of preeclampsia (P <.05). Vascular endothelial growth factor concentrations were associated with the elevated total peripheral resistance observed during the clinical disorder in the preeclampsia group but not in the other groups.
CONCLUSION: Maternal plasma vascular endothelial growth factor concentrations increased before the clinical onset of preeclampsia and were further elevated during the vasoconstricted state observed in this disorder. We speculate that the hyperdynamic circulation that characterizes the latent phase of preeclampsia causes vascular shear stress, which in turn increases the levels of circulating vascular endothelial growth factor. Because vascular endothelial growth factor normally acts as a vasodilator, its increase may represent an unsuccessful vascular rescue response.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11174494     DOI: 10.1067/mob.2001.108342

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  24 in total

1.  Intraabdominal fat, insulin sensitivity, and cardiovascular risk factors in postpartum women with a history of preeclampsia.

Authors:  Darcy R Barry; Kristina M Utzschneider; Jenny Tong; Kersten Gaba; Daniel F Leotta; John D Brunzell; Thomas R Easterling
Journal:  Am J Obstet Gynecol       Date:  2015-05-21       Impact factor: 8.661

2.  Cardiac myeloperoxidase activity is elevated in hypertensive pregnant rats.

Authors:  Ming-Lin Zhu; Jin-Ping Zhao; Ning Cui; Victor H Gonçalves-Rizzi; Jose S Possomato-Vieira; Regina A Nascimento; Carlos A Dias-Junior
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2017-12-21

3.  Effects of angiogenic factors, antagonists, and podocyte injury on development of proteinuria in preeclampsia.

Authors:  Guixiang Chen; Lihong Zhang; Xiaohong Jin; Yunjiao Zhou; Jianying Niu; Jing Chen; Yong Gu
Journal:  Reprod Sci       Date:  2012-09-18       Impact factor: 3.060

4.  Positive versus negative effects of VEGF165 on Ca2+ signaling and NO production in human endothelial cells.

Authors:  Derek S Boeldt; Jennifer Krupp; Fu-Xian Yi; Nauman Khurshid; Dinesh M Shah; Ian M Bird
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-11-11       Impact factor: 4.733

5.  A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia.

Authors:  Juan Pedro Kusanovic; Roberto Romero; Tinnakorn Chaiworapongsa; Offer Erez; Pooja Mittal; Edi Vaisbuch; Shali Mazaki-Tovi; Francesca Gotsch; Samuel S Edwin; Ricardo Gomez; Lami Yeo; Agustin Conde-Agudelo; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2009-11

6.  Sodium hydrosulfide prevents hypertension and increases in vascular endothelial growth factor and soluble fms-like tyrosine kinase-1 in hypertensive pregnant rats.

Authors:  Jose Sergio Possomato-Vieira; Victor Hugo Gonçalves-Rizzi; Tamiris Uracs Sales Graça; Regina Aparecida Nascimento; Carlos A Dias-Junior
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-09-12       Impact factor: 3.000

7.  Pregnancy-induced hypertension and preeclampsia: levels of angiogenic factors in malaysian women.

Authors:  Suseela Yelumalai; Sekaran Muniandy; Siti Zawiah Omar; Rajes Qvist
Journal:  J Clin Biochem Nutr       Date:  2010-10-29       Impact factor: 3.114

8.  Evidence of an imbalance of angiogenic/antiangiogenic factors in massive perivillous fibrin deposition (maternal floor infarction): a placental lesion associated with recurrent miscarriage and fetal death.

Authors:  Amy E Whitten; Roberto Romero; Steven J Korzeniewski; Adi L Tarca; Alyse G Schwartz; Lami Yeo; Zhong Dong; Sonia S Hassan; Tinnakorn Chaiworapongsa
Journal:  Am J Obstet Gynecol       Date:  2013-01-17       Impact factor: 8.661

9.  Differential expression of vascular endothelial growth factor (VEGF), endocrine gland derived-VEGF, and VEGF receptors in human placentas from normal and preeclamptic pregnancies.

Authors:  Jin-Young Chung; Yang Song; Yuping Wang; Ronald R Magness; Jing Zheng
Journal:  J Clin Endocrinol Metab       Date:  2004-05       Impact factor: 5.958

Review 10.  Vasodilator factors in the systemic and local adaptations to pregnancy.

Authors:  Gloria Valdes; Peter Kaufmann; Jenny Corthorn; Rafaela Erices; K Bridget Brosnihan; Janae Joyner-Grantham
Journal:  Reprod Biol Endocrinol       Date:  2009-07-31       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.